Lactose (India) Ltd

Lactose (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Lactose (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Lactose (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 30 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Lactose (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical indicators and financial performance metrics. While the stock has shown signs of technical recovery, its financial fundamentals present a complex picture, prompting a reassessment of its investment profile.

Lactose (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed analysis of its quality, valuation, financial trends, and technical indicators. Despite some positive quarterly financial results, the stock’s recent performance and underlying fundamentals have prompted a reassessment of its investment profile.

Lactose (India), a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a revision in its market evaluation metrics. This shift reflects a nuanced reassessment of the company’s financial and technical parameters, set against a backdrop of fluctuating stock returns and sector dynamics.

Lactose (India) Ltd is experiencing notable buying activity, with a significant stock increase today and a strong performance over the past week. The stock has shown resilience despite earlier challenges, reflecting a positive trend in the pharmaceuticals and biotechnology sector, supported by robust buyer sentiment.

Lactose (India) reported strong financial metrics for the quarter ending September 2025, with record net sales of Rs 41.18 crore and a robust operating profit to interest ratio. However, challenges persist, including negative operating cash flow and a significant decline in profit after tax over the nine-month period.

Lactose (India) Ltd., a Gujarat-based pharmaceutical and dairy products manufacturer, reported net profit of ₹2.16 crores for Q2 FY26, marking a 44.00% sequential increase from ₹1.50 crores in Q1 FY26 and a 6.40% rise from ₹2.03 crores in Q2 FY25. Despite the profit growth, the company's shares have struggled significantly, plunging 36.14% over the past year and trading at ₹107.70 as of November 14, 2025, reflecting investor concerns about operational efficiency and margin sustainability.

Lactose (India), a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a recent evaluation adjustment reflecting ongoing challenges. The company's performance indicators present a mixed outlook, with concerns over its high Debt to EBITDA ratio and significant profit decline, contributing to its underperformance against broader market indices.

Lactose (India) Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, recently experienced a Golden Cross, indicating a potential shift in momentum. Despite a challenging year with a 45.51% decline, the stock has risen 447.21% over five years, outperforming the Sensex significantly.